News and Insights

Pharmaceuticals and Medical Devices

Building Value Considerations into R&D

eyeforpharma

With spiraling cost inflation and lagging quality indicators driving a transition to a value-based system, public and private payers are using sophisticated tools, including health technology assessment (HTA), to evaluate the benefits of medicines. In this environment, companies must demonstrate both clinical efficacy and differentiated economic value to gain optimal…

Transparency Around Value to Support Rational Pricing Discussions

eyeforpharma

The issue of drug pricing has become a staple of the news cycle, with fresh headlines every few weeks spotlighting either the high cost of new breakthrough drugs like Sovaldi, or jaw-dropping price hikes for existing, popular products like the EpiPen. While these examples represent two very different sets of…

The Numerof 2017 Global Medical Device Outlook

Infographic

As our Numerof 2017 Global Medical Device Outlook infographic illustrates, this year’s story for medical device manufacturers will be about dramatically changing roles and relationships.  You’ll continue to engage in new and different ways with regulators, public and private payers, consumers, employers, health care delivery, physicians, retail clinics, and even…

The Numerof 2017 Global Pharma Outlook

Infographic

As our Numerof 2017 Global Pharma Outlook infographic illustrates, this year’s story for pharmaceutical manufacturers will be about adapting to evolving pressures on price and demands for value.  This will create the need for changes in current roles and external relationships.  You’ll continue to engage in new and different ways…

Barriers to Realizing Biosimilars’ Potential

PM360

For quite some time, providers, public and private payers, policy-makers, pharmacy benefit managers and patients have hoped the arrival of biosimilars would usher in a new era of competitive drug prices. However, as the U.S. market prepares to welcome its second biosimilar, Celltrion’s Inflectra, the future of biosimilars in this…

Value-Based Payment Models: Implications for Medical Device Manufacturers

MD&DI

The healthcare industry is facing enormous pressure in the form of spiraling cost inflation, lagging quality indicators, rising insurance premiums, and increased demand for price transparency to deliver better health outcomes at lower prices. The historical fee-for-service business model that rewards the volume of treatments and encourages unnecessary care without…